BOSTON & TORONTO -- Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP.

“Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the receipt of all necessary approvals. Our new identity represents who we are today and where we expect to be tomorrow—an innovative company focused on redefining mental health care with the goal of helping minds heal.”

The evolution of the Company reflects its ongoing transformation as a global clinical stage discovery and development company to a commercial pharmaceutical company poised to deliver NSAs as groundbreaking therapies through rigorous patient-centered research and clinical excellence. These proprietary NSAs are purposefully designed to unlock healing of the mind and allow individuals to achieve durable recovery.

The Company has transferred its U.S. stock exchange listing from the NYSE American (previous ticker: CYBN) to the Nasdaq trading under the ticker symbol “HELP”. The Company will continue to be listed on the Cboe Canada and will trade under the same “HELP” ticker symbol. The Company expects to seek approval from shareholders to change its legal name to Helus Pharma Inc. at the Company’s next annual and special meeting of shareholders.

The Company’s lead programs include:

·HLP003 (previously referred to as CYB003): a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration; and
·HLP004 (previously referred to as CYB004): a proprietary NSA in a Phase 2 study for generalized anxiety disorder.

“This is an exciting new chapter for the Company,” added Mr. So. “With key data readouts for both HLP003 and HLP004 expected in 2026, we believe we are well positioned for commercialization with the potential to significantly enhance patient outcomes, introduce innovative therapies for healthcare providers, and deliver value to payers and shareholders.”